Business, energy, technology, markets and global industry news from Business News Today

neurology

PharmaDeviceNews neurology
Representative image: Biologic vial and infusion setup for multiple sclerosis care, highlighting Teva Pharmaceutical Industries’ Polpharma Biologics deal for a proposed ocrelizumab biosimilar.
Pharma & Biotech

Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal

Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,

Read More
Representative image: A neurological researcher reviews advanced brain scans as uniQure prepares a potential FDA filing for AMT-130, its experimental gene therapy designed to slow Huntington’s disease progression.
Pharma & Biotech

FDA accepts uniQure’s AMT-130 filing strategy after months of regulatory uncertainty

Explore why the FDA reopened uniQure’s AMT-130 approval path and what evidence, surgical and confirmatory trial risks remain before review.

Read More
Representative image of a pediatric mobility assessment, highlighting how cTAP’s new Duchenne muscular dystrophy prognostic score could help predict loss of ambulation and improve DMD trial design.
Pharma & Biotech

Could cTAP’s new Duchenne prognostic score change how DMD trials measure mobility risk?

Find out how cTAP’s Duchenne prognostic score could improve DMD trial design and loss of ambulation prediction.

Read More
Representative image of CNS drug development and neuroscience research, highlighting Enveric Biosciences’ EB-003 push toward clinical-stage neuroplastogen testing.
Pharma & Biotech

Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development

Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.

Read More
Representative image of a rare disease neurology consultation, illustrating how Sanofi’s venglustat FDA priority review could change treatment options for type 3 Gaucher disease.
Pharma & Biotech

Can Sanofi’s venglustat priority review change the treatment outlook for type 3 Gaucher disease?

Sanofi’s venglustat could target neurological type 3 Gaucher disease. The FDA review now tests whether rare disease care can shift.

Read More
Pharma & Biotech

Emalex Biosciences advances Tourette syndrome strategy as ecopipam delays relapse in Phase 3 trial

D1 receptor targeting may change Tourette syndrome care. Ecopipam’s Phase 3 data now face the bigger test: regulation and adoption.

Read More
Representative image: A subcutaneous Alzheimer’s treatment injector is shown in a clinical consultation setting as Eisai Co., Ltd. and Biogen Inc. await the FDA’s August 2026 decision on Leqembi Iqlik as a starting dose for early Alzheimer’s disease.
Pharma & Biotech

FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy

Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.

Read More
Representative image: Angelini Pharma’s $4.1 billion Catalyst Pharmaceuticals acquisition highlights the growing race for rare disease and neurology assets, with Firdapse, Agamree and U.S. commercial scale at the center of the deal.
Pharma & Biotech

Angelini Pharma bets $4.1bn on rare neurology scale with Catalyst Pharmaceuticals

Angelini gains U.S. rare disease scale. Catalyst gets certainty, but Firdapse concentration keeps the real test ahead.

Read More
Pharma & Biotech

Is this the migraine breakthrough Big Pharma missed? Kallyope’s elismetrep hints at a whole new treatment playbook

Kallyope’s elismetrep migraine data point to a new TRPM8 treatment pathway. Find out what Phase 3 could prove next.

Read More
Pharma & Biotech

Why CervoMed Inc.’s neflamapimod findings may reshape biomarker-driven trials in dementia with Lewy bodies

CervoMed Inc. reveals neflamapimod MRI data in DLB. Discover how biomarker-driven trials could reshape neurodegeneration drug development.

Read More